Study #2015-0921
Phase II Study of Inotuzumab Ozogamicin in Patients with B-cell Lineage Acute Lymphocytic Leukemia with Positive Minimal Residual Disease
Study Status
Open
Treatment Agent
Inotuzumab Ozogamicin
Principal Investigator
Elias Jabbour
Description
The goal of this clinical research study is to learn how well low-dose inotuzumab ozogamicin may help to control acute lymphocytic leukemia (ALL). The safety of the study drug will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Inotuzumab Ozogamicin
Treatment Location: Only at MDACC
Sponsor: Pfizer, Inc. (Supporter)
Study Status
IRB Review and Approval Date: 02/15/2018
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789